AVEO Oncology to Participate in Upcoming Conferences
September 25 2018 - 7:00AM
Business Wire
AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO) today announced that
Michael Bailey, president and chief executive officer, will present
at the following investor conferences:
- 2018 Cantor Global Healthcare
Conference on Tuesday, October 2, 2018 at 4:00 p.m. Eastern Time.
The conference is being held at the Intercontinental New York
Barclay Hotel.
- Leerink Partners Roundtable Series:
Rare Disease & Oncology on Wednesday, October 3, 2018 at 1:00
p.m. Eastern Time. The conference is being held at the Lotte New
York Palace Hotel.
A live webcast of the presentations can be accessed by visiting
the investors section of the Company’s website at
www.aveooncology.com. A replay of the webcast will be archived for
30 days following the presentation date.
About AVEO Pharmaceuticals, Inc .
AVEO Pharmaceuticals, Inc. (the “Company”) is a
biopharmaceutical company dedicated to advancing a broad portfolio
of targeted medicines for oncology and other areas of unmet medical
need. The Company’s strategy is to retain North American rights to
its oncology portfolio while securing partners in development and
commercialization outside of North America. The Company is seeking
to develop and commercialize its lead candidate tivozanib in North
America as a treatment for advanced renal cell carcinoma (“RCC”).
The Company has outlicensed tivozanib (FOTIVDA®) for oncology in
Europe and other territories outside of North America. Tivozanib is
approved in the European Union, as well as Norway and Iceland, for
the first-line treatment of adult patients with RCC and for adult
patients who are vascular endothelial growth factor receptor and
mTOR pathway inhibitor-naïve following disease progression after
one prior treatment with cytokine therapy for RCC. The Company has
entered into partnerships to fund the development and
commercialization of AV-203 (CAN017) and ficlatuzumab, both
clinical stage assets in oncology. The Company is currently seeking
a partner to develop the AV-353 platform, a preclinical asset,
worldwide for the potential treatment of pulmonary arterial
hypertension. The Company has recently regained the rights to its
AV-380 program for the potential treatment of cachexia and is
considering a variety of options to advance the program’s
development.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Actual results or events
could differ materially due to a number of important factors,
including risks discussed in the section titled “Risk Factors” in
AVEO’s most recent Annual Report on Form 10-K, its quarterly
reports on Form 10-Q and its other filings with the SEC. The
forward-looking statements in this press release represent AVEO’s
views as of the date of this press release. AVEO anticipates that
subsequent events and developments may cause its views to change.
While AVEO may elect to update these forward-looking statements at
some point in the future, it specifically disclaims any obligation
to do so. You should, therefore, not rely on these forward-looking
statements as representing AVEO’s views as of any date other than
the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180925005295/en/
AVEO:Argot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Sep 2023 to Sep 2024